Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Fidaxomicin, a potent macrolide antibiotic renowned for its ability to impede bacterial growth and reproduction by disrupting metabolic pathways within bacterial cells, holds promi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：319
Clostridium difficile, a prevalent enteric pathogen, is known to induce profound diarrhea and occasionally necessitate hospitalization. Fidaxomicin, a therapeutic agent, aids in th···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：280
Fidaxomicin, a macrolide antibiotic sanctioned by the US FDA in 2011, boasts a distinctive mechanism of action. This medication predominantly hinders the RNA polymerase of bacteria···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：314
Fidaxomicin, a potent macrolide antibiotic, is primarily utilized in the treatment of infections attributed to specific bacterial strains, serving as a pivotal therapeutic agent ag···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：282
Fidaxomicin is a pharmaceutical agent specifically indicated for the treatment of diarrhea associated with Clostridium difficile. The assessment of the gravity of adverse events st···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：255
Fidaxomicin, a potent antibiotic medication, serves as a pivotal remedy for the treatment of diarrheal conditions stemming from a Clostridium difficile infection, showcasing signif···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：276
Anamorelin represents a pioneering intervention for cancer-associated cachexia, devised to mitigate the deterioration of nutritional status and weight loss prevalent in individuals···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：324
Through its distinctive mechanism of action, Anamorelin presents novel therapeutic modalities for individuals afflicted by cachexia, thereby enhancing their nutritional state and e···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：266
Fidaxomicin is indicated for the treatment of difficult Clostridioides difficile-associated diarrhea in adults and children aged 6 months and above. Fidaxomicin hastwo main differe···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：345
Anamorelin, a pharmaceutical agent, is utilized in the treatment of specific maladies through its modulation of intricate biochemical pathways within the human organism. Widely emp···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：297
Anamorelin, a prominent anti-cachexia drug utilized in the treatment of cancer patients, has seen fluctuations in its pricing due to advancements in medical technology and increase···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：302
Sotorasib, an innovative medication targeting specific genetic mutations in non-small cell lung cancer (NSCLC), has emerged as a novel option for treating this disease owing to its···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：299
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3372025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3272025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：3012025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
